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Acanthamoeba polyphaga mimivirus (APM), a virus of 
free-living amebae, has reportedly caused human respirato-
ry disease. Using 2 newly developed real-time PCR assays, 
we screened 496 respiratory specimens from 9 pneumonia-
patient populations for APM. This virus was not detected in 
any specimen, which suggests it is not a common respira-
tory pathogen.
I
nvestigation of a suspected Legionnaire’s pneumonia 
outbreak in 1992 led to the isolation of a new microor-
ganism from a water cooling tower in Bradford, England. 
This pathogen was thought to be a bacterium because it 
resembled small gram-positive cocci; however, in 2003 
it was correctly identiﬁ  ed as a virus (1). Acanthamoeba 
polyphaga mimivirus (APM), named for its ameba host and 
bacteria-mimicking characteristics, is a double-stranded 
DNA virus with the largest viral genome described to date 
(1.2 Mb) (2). Mimiviridae is the newest member of the nu-
cleocytoplasmic large DNA virus (NCLDV) group, which 
also contains Poxviridae, Iridoviridae, Asfarviridae, and 
Phycodnaviridae  (1). APM encodes speciﬁ  c  translation 
proteins that are more commonly associated with cellular 
organisms than with viruses (2).
Other ameba-associated microorganisms from environ-
mental sources, such as Legionella pneumophila, are known 
to cause outbreaks of acute pneumonia in immunosuppressed 
and elderly persons, although person-to-person transmission 
is uncommon. Whether APM is similarly responsible for in-
dividual cases or outbreaks of respiratory disease has yet to 
be conclusively determined. Previous studies have reported 
serologic evidence of APM infection in 7.1% to 9.7% of pa-
tients with community- or nosocomially acquired pneumonia 
(3,4). APM DNA was also ampliﬁ  ed by a nested PCR assay 
from a bronchoalveolar lavage specimen of a 60-year-old 
patient receiving intensive care for hospital-acquired pneu-
monia (3). In this study, we used newly developed real-time 
PCR assays to screen pneumonia patients from a variety of 
epidemiologic settings for APM infections.
The Study
Real-time PCR assays for APM were developed from 
multiple primers and probes designed for conserved re-
gions of class I NCLDV genes L396 and R596, class III 
NCLDV gene L65, as well as the R656 gene, from the 
published APM genome sequence (GenBank accession 
no. NC_006450) by using Primer Express 3.0 software 
(Applied Biosystems, Foster City, CA, USA). All probes 
were labeled at the 5′ end with 6-carboxy-ﬂ  uorescein and 
quenched at the 3′ end with Black Hole Quencher-1 (Bi-
osearch Technologies, Novato, CA, USA). Different prim-
er and probe combinations were evaluated, and the 2 PCR 
assays that gave the best performance were selected for 
further studies (Table 1). Assays were performed by using 
the iQSupermix Kit (Bio-Rad, Hercules, CA, USA) in 25-
μL reaction volumes. Ampliﬁ  cation was performed on an 
iCycler iQReal-Time Detection System (Bio-Rad) by us-
ing the following cycling conditions: 95ºC for 3 min for 1 
cycle; 95ºC for 15 s and 55ºC for 1 min for 45 cycles each. 
Total nucleic acid was extracted from all specimens by us-
ing either the NucliSens Automated Extractor (bioMérieux, 
Boxtel, the Netherlands) or the automated BioRobot MDx 
(QIAGEN, Valencia, CA, USA) according to the manufac-
turers’ instructions. Each clinical specimen was also tested 
for the human ribonuclease P gene to measure nucleic acid 
integrity as previously described (5).
For PCR-positive controls, recombinant plasmids 
containing APM DNA (kindly provided by Didier Raoult, 
Unite des Rickettsies, Universite de la Mediterranee, Mar-
seille, France) were constructed. Primer pairs bracketing 
the L396 and R596 genes were used to amplify 1,560-
bp and 879-bp full gene regions, respectively, using 300 
nmol/L of forward primers 396 F (5′-TTA ATC ATC TTC 
CAA AAA ATT TAA TTC-3′) and 596 F (5′-ATG TCG 
TTA TCA AAA CAA GTA GTT CC-3′), and 300 nmol/L 
of reverse primers 396 R (5′-ATG GCG AAC AAT ATT 
AAA ACT AAA A-3′) and 596 R (5′-CTA ATT TTC AAT 
ATA GTG CGT AGA TTC TA-3′). These PCR products 
were puriﬁ  ed by using the QIAquick Gel Extraction Kit 
(QIAGEN) and then cloned into a pCR-II TOPO vector by 
using a TOPO TA Cloning Kit (Invitrogen, Carlsbad, CA, 
USA). Recombinant plasmids were then isolated by using 
the QIAprep Spin Miniprep Kit (QIAGEN) and quantiﬁ  ed 
by UV spectroscopy. Standard curves were prepared from 
serial 10-fold dilutions of the quantiﬁ  ed plasmid in nucle-
ase-free water containing 100 μg/mL of herring sperm 
DNA (Promega, Madison, WI, USA).
The L396 and R596 real-time PCR assays could de-
tect as few as 10 copies of plasmid DNA per reaction with 
ampliﬁ  cation efﬁ  ciencies of 99.6% [slope –3.33 and r2 = 
0.99] (Figure, left panels) and 99.2% [slope –3.34 and r2 = 
1.00] (Figure, right panels), respectively. No ampliﬁ  cation 
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USA.was obtained by either assay with pooled total nucleic acid 
extracts from respiratory samples from healthy humans or 
from other common DNA respiratory viruses, including 
adenovirus, human bocavirus, or herpesviruses. 
The real-time PCR assays were used to test respiratory 
specimens from 496 pneumonia cases representing 9 distinct 
patient populations, which consisted of hospitalized pneu-
monia patients from population-based pneumonia surveil-
lance studies in Thailand and the United States, transplant re-
cipients with pneumonia, and isolated pneumonia outbreaks 
in either retirement homes for the elderly or familial clusters 
(Table 2). Of the 496 specimens tested, no positive results 
were obtained for APM DNA by either assay.
Conclusions
We developed a rapid method of screening samples 
for APM DNA by using 2 sensitive and speciﬁ  c real-
time PCR assays designed to target conserved NCLDV 
class I genes. With only 1 APM sequence published 
(NC_006450) (2), little is known of APM strain variation; 
therefore, use of assays that target different genes increas-
es the likelihood that genetic variants of APM will not be 
missed. A suicide-nested PCR method for APM detection 
has been reported (3); however, the quicker turnaround 
time and lower risk for amplicon contamination makes the 
real-time PCR method more attractive for screening large 
numbers of samples.
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Table 1. Primer and probe sequences for Acanthamoeba polyphaga mimivirus real-time PCR assays 
Target  Primer/probe  Gene region  Sequence (5ƍĺ3ƍ) 
Forward    ACC TGA TCC ACA TCC CAT AAC TAA A 
Reverse  Helicase  GGC CTC ATC AAC AAA TGG TTT C 
APM-396 
Probe    ACT CCA CCA CCT CCT TCT TCC ATA CCT TT 
Forward    AAC AAT CGT CAT GGG AAT ATA GAA AT 
Reverse  Thiol oxidoreductase  CTT TCC AGT ATC CCT GTT CTT CAA 
APM-596 
Probe    TTC GTC ATA TGC GAG AAA ATG CTA TCC CT 
Figure. Real-time PCR ampliﬁ  cation plots and standard curves for Acanthamoeba polyphaga mimivirus (APM)-396 (A, A′) and APM-
596 (B, B’). Linear ampliﬁ  cation was achieved over 6 logs for both assays over 5 × 106 to 5 × 101 copies of plasmid DNA. RFU, relative 
ﬂ  uorescence units.Screening Pneumonia Patients for Mimivirus 
A seroprevalence study of APM among Canadian pa-
tients with community-acquired pneumonia identiﬁ  ed APM 
antibodies in 9.7% of 376 patients compared with 2.3% of 
511 healthy controls (3). However, seropositivity may re-
ﬂ  ect exposure to APM antigen rather than active infection, 
and the potential for nonspeciﬁ  c cross-reactions with the 
serologic assays used may have inﬂ  ated the true prevalence 
of APM infection (6). In a separate report, a laboratory-
acquired APM infection was linked to acute pneumonia by 
seroconversion in a technician in Marseille, France, thus 
providing evidence that this virus can occasionally cause 
clinical disease (7). However, using sensitive real-time 
PCR assays, we failed to detect APM DNA in 496 respira-
tory specimens from 9 epidemiologically varied pneumo-
nia patient populations.
If we assume an APM prevalence of 0.2% (1 case in 
the study sample), the estimated probability of obtaining 
our results by chance, based on binomial analysis, would 
be 0.37. Most of the specimens we tested were from the 
upper respiratory tract, whereas the only reported APM 
PCR–positive sample was from a lower respiratory bron-
choalveolar lavage specimen (3). Moreover, the patient 
populations sampled may not represent those at highest 
risk for APM infection. Nevertheless, our study supports 
the ﬁ  ndings of an Austrian study that failed to detect APM 
in 214 nasopharyngeal specimens from hospitalized chil-
dren with respiratory symptoms (8).
Our study did not detect APM in a large collection of 
specimens from patients with pneumonia, which indicates 
that this virus is not a common cause of severe acute re-
spiratory disease. Because APM is an ameba-associated 
pathogen like Legionella, exposures to APM are most like-
ly to occur from environmental sources. Further studies of 
more epidemiologically appropriate populations may be 
necessary to adequately access the importance of APM as 
a potential human respiratory pathogen. The real-time PCR 
assays described here will help facilitate these studies.
Mr Dare is a microbiologist in the Division of Viral and 
Rickettsial Diseases at the Centers for Disease Control and Pre-
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Table 2. Characteristics of 496 pneumonia patients tested for Acanthamoeba polyphaga mimivirus  DNA* 
Setting or population  Sample size Age group Sample type Location Period Other causes 
124 Children<5 y Nasal swabs Urban USA  Oct 2000–
Sep 2001
None detected Community-acquired 
pneumonia cases
120 Adults, children NP swabs Rural
Thailand
Sep 2003–
Aug 2004
None detected
23 Geriatric NP/OP swabs Retirement
center, USA
Sep 2003 20% rhinovirus
24 Geriatric NP/OP swabs Retirement
center, USA
Jul–Aug 2002 20% rhinovirus
Nosocomially acquired 
pneumonia outbreaks 
24 Geriatric Nasal swabs Retirement
center, USA
May 2004 50% hMPV
Community-acquired 
pneumonia outbreak 
5 Adults, children BAL, sputum, 
ET aspirate
Familial 
cluster, USA
Nov 2004 None detected
42 Adults NP aspirate USA Jan–Apr 2001 60% other respiratory 
viruses
Bone marrow transplant 
recipients
45 Adults Nasal wash, NP 
swabs
USA 2003 10% influenza and 
picornaviruses
Lung transplant 
recipients
89 Adults NP swabs Canada 2002–2003 30% other respiratory 
viruses
*NP, nasopharyngeal; OP, oropharyngeal; hMPV, human metapneumovirus; BAL, bronchoalveolar lavage; ET, endotracheal. 